Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma

Yu Chi Su, Goutham Venkata Naga Davuluri, Cheng Hao Chen, Dong Che Shiau, Chien Chin Chen, Chia Ling Chen, Yee Shin Lin, Chih Peng Chang

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers in Taiwan. Although chemotherapy is the primary treatment for HCC patients, drug resistance often leads to clinical failure. Galectin-1 is a beta-galactoside binding lectin which is up-regulated in HCC patients and promotes tumor growth by mediating cancer cell adhesion, migration and proliferation, but its role in chemoresistance of HCC is poorly understood. In this study we found that galectin-1 is able to lead to chemoresistance against cisplatin treatment, and subsequent inhibition has reversed the effect of cell death in HCC cells. Moreover, galectin- 1 was found to induce autophagic flux in HCC cells. Inhibition of autophagy by inhibitors or knockdown of Atg5 cancels galectin-1-induced cisplatin resistance in HCC cells. Increase of mitophagy triggered by galectin-1 was found to reduce the mitochondrial potential loss and apoptosis induced by cisplatin treatment. Finally, using an in situ hepatoma mouse model, we clearly demonstrated that inhibition of galectin-1 by thiodigalactoside could significantly augment the anti-HCC effect of cisplatin. Taken together, our findings offer a new insight into the chemoresistance galectin-1 causes against cisplatin treatment, and points to a potential approach to improve the efficacy of cisplatin in the treatment of HCC patients.

Original languageEnglish
Article numbere0148408
JournalPLoS One
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Galectin 1
cisplatin
autophagy
Autophagy
hepatoma
Cisplatin
Hepatocellular Carcinoma
Galectins
Chemotherapy
Cell adhesion
Mitochondrial Degradation
Cell death
Therapeutics
Neoplasms
Tumors
neoplasms
galactosides
drug resistance
cells
Taiwan

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Su, Y. C., Davuluri, G. V. N., Chen, C. H., Shiau, D. C., Chen, C. C., Chen, C. L., ... Chang, C. P. (2016). Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma. PLoS One, 11(2), [e0148408]. https://doi.org/10.1371/journal.pone.0148408

Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma. / Su, Yu Chi; Davuluri, Goutham Venkata Naga; Chen, Cheng Hao; Shiau, Dong Che; Chen, Chien Chin; Chen, Chia Ling; Lin, Yee Shin; Chang, Chih Peng.

In: PLoS One, Vol. 11, No. 2, e0148408, 01.02.2016.

Research output: Contribution to journalArticle

Su, YC, Davuluri, GVN, Chen, CH, Shiau, DC, Chen, CC, Chen, CL, Lin, YS & Chang, CP 2016, 'Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma', PLoS One, vol. 11, no. 2, e0148408. https://doi.org/10.1371/journal.pone.0148408
Su, Yu Chi ; Davuluri, Goutham Venkata Naga ; Chen, Cheng Hao ; Shiau, Dong Che ; Chen, Chien Chin ; Chen, Chia Ling ; Lin, Yee Shin ; Chang, Chih Peng. / Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma. In: PLoS One. 2016 ; Vol. 11, No. 2.
@article{1278532a7c8849bb9dca85ca079277ca,
title = "Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) is one of the most common cancers in Taiwan. Although chemotherapy is the primary treatment for HCC patients, drug resistance often leads to clinical failure. Galectin-1 is a beta-galactoside binding lectin which is up-regulated in HCC patients and promotes tumor growth by mediating cancer cell adhesion, migration and proliferation, but its role in chemoresistance of HCC is poorly understood. In this study we found that galectin-1 is able to lead to chemoresistance against cisplatin treatment, and subsequent inhibition has reversed the effect of cell death in HCC cells. Moreover, galectin- 1 was found to induce autophagic flux in HCC cells. Inhibition of autophagy by inhibitors or knockdown of Atg5 cancels galectin-1-induced cisplatin resistance in HCC cells. Increase of mitophagy triggered by galectin-1 was found to reduce the mitochondrial potential loss and apoptosis induced by cisplatin treatment. Finally, using an in situ hepatoma mouse model, we clearly demonstrated that inhibition of galectin-1 by thiodigalactoside could significantly augment the anti-HCC effect of cisplatin. Taken together, our findings offer a new insight into the chemoresistance galectin-1 causes against cisplatin treatment, and points to a potential approach to improve the efficacy of cisplatin in the treatment of HCC patients.",
author = "Su, {Yu Chi} and Davuluri, {Goutham Venkata Naga} and Chen, {Cheng Hao} and Shiau, {Dong Che} and Chen, {Chien Chin} and Chen, {Chia Ling} and Lin, {Yee Shin} and Chang, {Chih Peng}",
year = "2016",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0148408",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma

AU - Su, Yu Chi

AU - Davuluri, Goutham Venkata Naga

AU - Chen, Cheng Hao

AU - Shiau, Dong Che

AU - Chen, Chien Chin

AU - Chen, Chia Ling

AU - Lin, Yee Shin

AU - Chang, Chih Peng

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Hepatocellular carcinoma (HCC) is one of the most common cancers in Taiwan. Although chemotherapy is the primary treatment for HCC patients, drug resistance often leads to clinical failure. Galectin-1 is a beta-galactoside binding lectin which is up-regulated in HCC patients and promotes tumor growth by mediating cancer cell adhesion, migration and proliferation, but its role in chemoresistance of HCC is poorly understood. In this study we found that galectin-1 is able to lead to chemoresistance against cisplatin treatment, and subsequent inhibition has reversed the effect of cell death in HCC cells. Moreover, galectin- 1 was found to induce autophagic flux in HCC cells. Inhibition of autophagy by inhibitors or knockdown of Atg5 cancels galectin-1-induced cisplatin resistance in HCC cells. Increase of mitophagy triggered by galectin-1 was found to reduce the mitochondrial potential loss and apoptosis induced by cisplatin treatment. Finally, using an in situ hepatoma mouse model, we clearly demonstrated that inhibition of galectin-1 by thiodigalactoside could significantly augment the anti-HCC effect of cisplatin. Taken together, our findings offer a new insight into the chemoresistance galectin-1 causes against cisplatin treatment, and points to a potential approach to improve the efficacy of cisplatin in the treatment of HCC patients.

AB - Hepatocellular carcinoma (HCC) is one of the most common cancers in Taiwan. Although chemotherapy is the primary treatment for HCC patients, drug resistance often leads to clinical failure. Galectin-1 is a beta-galactoside binding lectin which is up-regulated in HCC patients and promotes tumor growth by mediating cancer cell adhesion, migration and proliferation, but its role in chemoresistance of HCC is poorly understood. In this study we found that galectin-1 is able to lead to chemoresistance against cisplatin treatment, and subsequent inhibition has reversed the effect of cell death in HCC cells. Moreover, galectin- 1 was found to induce autophagic flux in HCC cells. Inhibition of autophagy by inhibitors or knockdown of Atg5 cancels galectin-1-induced cisplatin resistance in HCC cells. Increase of mitophagy triggered by galectin-1 was found to reduce the mitochondrial potential loss and apoptosis induced by cisplatin treatment. Finally, using an in situ hepatoma mouse model, we clearly demonstrated that inhibition of galectin-1 by thiodigalactoside could significantly augment the anti-HCC effect of cisplatin. Taken together, our findings offer a new insight into the chemoresistance galectin-1 causes against cisplatin treatment, and points to a potential approach to improve the efficacy of cisplatin in the treatment of HCC patients.

UR - http://www.scopus.com/inward/record.url?scp=84959217460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959217460&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0148408

DO - 10.1371/journal.pone.0148408

M3 - Article

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0148408

ER -